Improving the life of patients through targeted molecular diagnostics and therapies

Compounds administered to more than 1300 patients

CXCR4 compound extensively studied in 150+ scientific papers

Two Phase-III-ready drug candidates

Team of 40 employees with > 50% Ph.D. ratio

Latest News:

Empfohlen
First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium-90 Anditixafortide (PentixaTher)
Read More →
EANM 2023: The theranostics future is now: Innovative diagnostic application and therapeutic potential of CXCR4 
Read More →
PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
Read More →
Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
Read More →
Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
Read More →
First CNS Lymphoma Patient Imaged with PentixaFor in Phase II Trial
Read More →
Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR
Read More →
Nantes University Hospital Doses First Patients with Eckert & Ziegler's Novel Ga-68 Imaging Agent PENTIXAFOR
Read More →
Eckert & Ziegler Strahlen- und Medizintechnik AG Acquires Direct Majority Stake in Drug Developer PENTIXAPHARM
Read More →
PENTIXAPHARM receives confirmation from EMA that its Lead Candidate PENTIXAFOR is ready for Phase III Study
Read More →
PENTIXAPHARM Secures € 15 Million Series A Financing to Develop CXCR4-Targeted Theranostics
Read More →